Google
OKYO 株価分析 — Okyo Pharma LTD ADR (Healthcare >> Biotechnology)
OKYO に関するよくある質問
OKYOのROE（自己資本利益率）は？
Okyo Pharma LTD ADRのROEは-105.41%です。
OKYOの配当利回りは？
Okyo Pharma LTD ADRの配当利回りは0.00%です。
OKYOの品質スコア（Quality Score）は？
当社のAIはOKYOの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
OKYOは今が買い時ですか？
当社AIのタイミングスコアは100点中63点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
OKYOはどのセクターに属しますか？
Okyo Pharma LTD ADRはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
OKYO AI Analysis Summary
Our AI summary for OKYO: Okyo Pharma LTD ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -105.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 63/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.57
Price
-0.07
(-4.27%)
Day Change
|
|
|---|
OKYO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.57 |
| PBV / Sector |
6.98 / 44,105.10
|
| Earning Per Share | -0.24 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.21 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:27 |
| Symbol | OKYO |
| Name | OKYO PHARMA LTD ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 86.07 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 14/15 Conduit St, London, United Kingdom, W1S 2XJ
Phone: 44 20 7495 2379
Website: https://okyopharma.com
Sector: Healthcare >> Biotechnology
Description: OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
